Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Western Australia, Australia.
Intern Med J. 2022 Apr;52(4):633-639. doi: 10.1111/imj.15104.
Barrett oesophagus is a known precursor of oesophageal adenocarcinoma (EAC). Early EAC includes T1a (invasion into mucosa) and T1b (invasion into submucosa but not muscularis propria). Endoscopic mucosal resection (EMR) provides accurate histological staging and definitive treatment for early EAC. Post EMR, the remaining Barrett is eradicated with radiofrequency ablation (RFA). However, there is a paucity of long-term Australian data.
To investigate the efficacy and long-term outcomes of EMR and RFA in the management of early EAC.
Retrospective analysis of patients early EAC treated endoscopically at three Western Australian tertiary centres, with at least 12-months follow up, over the past 10 years.
Sixty-seven patients with early EAC (61 T1a and 6 T1b) were treated with EMR. Complete Barrett eradication was done by EMR in 31 of 67 patients whereas 36/67 patients underwent RFA for residual Barrett. EMR changed pinch biopsy histology from HGD (n = 33), HGD suspicious for IMC (n = 5) and LGD (n = 1) to early EAC in 58.2% (n = 39) patients. During a mean follow up of 37.2 months (interquartile range: 20, 56), complete remission of dysplasia and intestinal metaplasia was seen in 97% (n = 65) and 89.5% (n = 60) patients. One patient with T1b EAC underwent oesophagectomy. No cases developed metachronous EAC, progression to invasive adenocarcinoma or development of nodal/distant metastasis. Complications were endoscopically treated haematemesis (n = 1) and strictures (n = 16) requiring dilatations. Three patients died due to causes unrelated to IMC.
EMR in conjunction with RFA is an effective and safe management for early EAC. EMR provides accurate staging and has low complication rates.
巴雷特食管是食管腺癌(EAC)的已知前体。早期 EAC 包括 T1a(侵犯黏膜)和 T1b(侵犯黏膜下层但未侵犯固有肌层)。内镜黏膜切除术(EMR)为早期 EAC 提供准确的组织学分期和明确的治疗。EMR 后,用射频消融(RFA)消除剩余的巴雷特。然而,澳大利亚缺乏长期数据。
探讨 EMR 和 RFA 在早期 EAC 治疗中的疗效和长期结果。
对过去 10 年来在西澳大利亚 3 个三级中心接受内镜治疗的早期 EAC 患者进行回顾性分析,随访时间至少 12 个月。
67 例早期 EAC 患者(61 例 T1a 和 6 例 T1b)接受 EMR 治疗。67 例患者中,31 例通过 EMR 完全根除巴雷特,36 例因残留巴雷特而行 RFA。EMR 将 33 例高度异型增生(HGD)、5 例疑似黏膜内癌(IMC)的 HGD 和 1 例低级别瘤变(LGD)的活检组织学改变为早期 EAC,占 58.2%(n=39)。在平均 37.2 个月(四分位距:20,56)的随访中,97%(n=65)和 89.5%(n=60)的患者完全缓解了异型增生和肠上皮化生。1 例 T1b EAC 患者行食管切除术。无病例发生异时性 EAC、进展为浸润性腺癌或发生淋巴结/远处转移。并发症为内镜治疗的呕血(n=1)和狭窄(n=16),需要扩张。3 例患者因与 IMC 无关的原因死亡。
EMR 联合 RFA 是早期 EAC 的有效且安全的治疗方法。EMR 提供准确的分期,并发症发生率低。